Thyroid Dysfunction following Radiotherapy and Combined Therapy in Non-Thyroid Head and Neck Cancers by Rais Ahmad Bhat, Om Prakash, Shabab Lalit Angurana

Subjects: Get full text

Colorectal cancer spectrum: From subtypes and epidemiology to oncotherapies by Nidhi Agrawal, S.K. Lanjhiyana, Meenakshi Jaiswal, Mohammad Akbar Siddiqui, Sakshi Gupta

Subjects: Get full text

The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis by Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang

“…The outcomes were defined as incidence of FN in the first cycle and among all cycles of chemotherapy using three different definitions for FN. …”
Get full text

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, Fuxing Zhao, Zitao Li, Shifen Huang, Yongzhi Chen, Yingjian He, Yan Liu, Zijun Zhu, Yongxin Li, Jinming Li, Mengting Da, Hongnan Mo, Feng Du, Liang Cui, Jing Bai, Zhen Liu, Fei Ma, Jiuda Zhao

“…Abstract We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). …”
Get full text

Influence of symptom burden on social alienation in lung cancer patients receiving chemotherapy: the chain mediating effect of perceived social support and positive psychological capital by Jiahao Wei, Ziye Bai, Mengru Bu, Guining Dang, Xiumei Wu, Jin Zhou

Subjects: “…Lung cancer chemotherapy…”
Get full text

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial by Run-Cong Nie, Shu-Qiang Yuan, Ya Ding, Yong-Ming Chen, Yuan-Fang Li, Cheng-Cai Liang, Mu-Yan Cai, Guo-Ming Chen, Wei Wang, Xiao-Wei Sun, De-Sheng Weng, Dan-Dan Li, Jing-Jing Zhao, Xiao-Jiang Chen, Yuan-Xiang Guan, Zhi-Min Liu, Yao Liang, Ma Luo, Jun Chi, Hai-Bo Qiu, Zhi-Wei Zhou, Xiao-Shi Zhang, Ying-Bo Chen

“…Abstract This prospective, nonrandomized, open-label phase 2 trial (Chinese Clinical Trial Registry, ChiCTR2200061906) aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locally advanced gastroesophageal junction adenocarcinoma (GEJA). …”
Get full text

Circadian rhythm related genes signature in glioma for drug resistance prediction: a comprehensive analysis integrating transcriptomics and machine learning by Junbo Liao, Yingxing Duan, Xiangwang Xu, Yaxue Liu, Chaohong Zhan, Gelei Xiao

Subjects: Get full text

Endometrial Carcinoma Presenting with an Isolated Osseous Metastasis: A Case Report by Nesrine Tounsi, Ines Zemni, Fatma Saadalah, Maher Slimane, Nadia Boujelbene, Mohamed ali Ayadi, Chargui Rhiad, Rahal Khaled

Subjects: Get full text

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy by November McGarvey, Hairong Xu

“…**Background:** Anemia is a common complication among patients with cancer receiving chemotherapy and can cause significant costs to health plans. …”
Get full text

Treatment and outcomes of high-risk neuroblastoma in Southeast Asia: a single-institution experience and review of the literature by Anselm Chi-Wai Lee, Chan Hon Chui, Robert Kwok, Kim Shang Lee, Chee Meng Fong, Wilfred Hing-Sang Wong

Subjects: “…chemotherapy…”
Get full text

Editorial: Drug repurposing for cancer treatment: current and future directions by Marios Lampros, Nikolaos Vlachos, Georgios D. Lianos, Christina Bali, George A. Alexiou

Subjects: Get full text

Advances in sodium-glucose transporter protein 2 inhibitors and tumors by Jiaqi Wang, Wenyong Yang

Subjects: Get full text

Exploration of the quantitative-effectiveness association between acupuncture temporal parameters and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis of randomized controlled trials by Hao Tian, Qin Luo, Liuyang Huang, Liuyang Huang, Liuyang Huang, Guang Chen, Mingsheng Sun, Fanrong Liang

Subjects: Get full text

Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial by Michael Ghadimi, Uwe Pelzer, Marc G. Besselink, Jens Siveke, Ralph Telgmann, Rickmer Braren, Hanneke Wilmink, Marie Crede, Alexander Koenig, Ute Koenig, Sven Thorsten Liffers, Kai Antweiler, Bas Uijterwijk, Hanna Seppanen, Arno Nordin, Pauli Puolakkainen, Olav F. Dajani, Knut Jørgen Labori, Mia Johansson, Svein Olav Bratlie, Tim Friede, Peter Jo

Subjects: Get full text

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy by Meifeng Luo, Huiting Wei, Moqin Qiu, Cuiyun Su, Ruiling Ning, Shaozhang Zhou

Subjects: Get full text

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis by Weiming Liang, Weiming Liang, Zhijing Wang, Zhilong Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Duo Zhang, Chenchen Li

“…ObjectiveTo evaluate the efficacy and safety of programmed cell death protein 1 or its ligand (PD-1/L1) inhibitors as first-line therapy in advanced or metastatic urothelial carcinoma (mUC) who are ineligible for platinum-based chemotherapy.MethodA systematic search was conducted in four databases (Pubmed, Embase, Web of Science, and the Cochrane Library) to find articles that evaluate the effectiveness of first-line PD-1/L1 inhibitors for mUC, from the establishment of the databases to 22 November 2023. …”
Get full text

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy by Huanhuan Li, Chao Ren, Donghai Cui, Tao Wu, Zhiyong Nie

“…The patient received three cycles of pembrolizumab plus trastuzumab and chemotherapy preoperatively and underwent radical surgery on November 22, 2022.ConclusionPatients with HER-2-positive locally advanced GEJ cancers received PD-1 immunotherapy combined with trastuzumab and neoadjuvant chemotherapy and achieved a complete pathological response. …”
Get full text

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy) by Yingyi Li, Yuqin Cao, Xipeng Wang, Chengqiang Li, Liqin Zhao, Hecheng Li

“…Considering the differences in chemotherapy regimen tolerance between Asian and Western populations, this study intends to evaluate the suitability of Adebrelimab combined with XELOX chemotherapy for the Asian population. …”
Get full text

A Retrospective Observational Cohort Analysis of Oncology Patients with Febrile Neutropenia in the Emergency Department of a Tertiary Care Hospital in Oman by Badar Al-Aamri, Aisha AL Breiki, Darpanarayan Hazra, Talib Al-Aamri, Manar Al-Shehi

Subjects: Get full text

Uterine endometrioid adenocarcinoma with pilomatrix-like differentiation: A case report and review of the literature by L. Rusnell, Z. Al-Shamma, S.P. Bisch

Subjects: Get full text